RT Journal Article
T1 Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models.
A1 Tena-Garitaonaindia, Mireia
A1 Arredondo-Amador, María
A1 Mascaraque, Cristina
A1 Asensio, Maitane
A1 Marin, Jose J G
A1 Martinez-Augustin, Olga
A1 Sanchez de Medina, Fermin
K1 Colitis
K1 Glucocorticoid
K1 IgA
K1 Intestinal barrier function
K1 Stress
AB Glucocorticoids (GCs) are widely used drugs for their anti-inflammatory and immunosuppressant effects, but they are associated with multiple adverse effects. Despite their frequent oral administration, relatively little attention has been paid to the effects of GCs on intestinal barrier function. In this review, we present a summary of the published studies on this matter carried out in animal models and cultured cells. In cultured intestinal epithelial cells, GCs have variable effects in basal conditions and generally enhance barrier function in the presence of inflammatory cytokines such as tumor necrosis factor (TNF). In turn, in rodents and other animals, GCs have been shown to weaken barrier function, with increased permeability and lower production of IgA, which may account for some features observed in stress models. When given to animals with experimental colitis, barrier function may be debilitated or strengthened, despite a positive anti-inflammatory activity. In sepsis models, GCs have a barrier-enhancing effect. These effects are probably related to the inhibition of epithelial cell proliferation and wound healing, modulation of the microbiota and mucus production, and interference with the mucosal immune system. The available information on underlying mechanisms is described and discussed.
PB Elsevier Ltd
YR 2022
FD 2022-01-01
LK http://hdl.handle.net/10668/22471
UL http://hdl.handle.net/10668/22471
LA en
NO ena-Garitaonaindia M, Arredondo-Amador M, Mascaraque C, Asensio M, Marin JJG, Martínez-Augustin O, et al. Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models. Pharmacol Res. 2022 Mar;177:106056.
NO his work was supported by the “Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)”, belonging to Instituto de Salud Carlos III, Spain, and grants from: Ministry of Economy and Competitivity, partly with Fondo Europeo de Desarrollo Regional FEDER funds [ SAF2017–88457-R , AGL2017–85270-R ]; “Junta de Andalucía”, Spain [CTS235, CTS164 ]; “Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III”, Spain ( PI19/00819 ), co-funded by European Regional Development Fund/European Social Fund, “Investing in your future”; “Junta de Castilla y León” ( SA074P20 ), Spain; “Fundació Marató TV3″ ( 201916–31), Spain; AECC Scientific Foundation (2017/2020), Spain; and “Centro Internacional sobre el Envejecimiento” (OLD-HEPAMARKER,  0348_CIE_6_E), Spain. 
DS RISalud
RD Apr 17, 2025